Group 1 - The "Shockwave Valve Treatment System" developed by Zhejiang University School of Medicine and Peijia Medical has been selected for the National Medical Products Administration's innovative medical device special review procedure, marking a significant breakthrough in the treatment of aortic valve calcification in China [1][3] - This system represents a shift from "artificial valve replacement" to "autologous valve repair," addressing the durability issues of implants for younger patients and the surgical challenges for complex calcified cases [1][2] - The technology utilizes advanced imaging guidance and energy control to precisely focus shockwave energy, effectively loosening calcified lesions while protecting surrounding healthy tissue, thus avoiding long-term complications associated with traditional implants [2] Group 2 - The inclusion of the Shockwave Valve Treatment System in the innovative channel reflects regulatory recognition of its originality and clinical value, which will accelerate its clinical trial and registration process [3] - Peijia Medical aims to expedite the clinical transformation of this technology to benefit a wide range of patients, especially in the context of the growing global population suffering from heart valve diseases [3] - The breakthrough signifies a new height in China's medical device innovation and indicates a shift towards more precise, minimally invasive, and personalized treatment for heart valve diseases [3]

Core Viewpoint - The article highlights the recent approval of seven innovative medical devices by the National Medical Products Administration, indicating a growing focus on medical technology innovation in China [1]. Group 1: Company Profiles - Zhihui Heart Medical Technology Co., Ltd., a subsidiary of Peijia Medical Group, focuses on the development and production of shock wave therapy systems for complex vascular diseases, with a total investment of 450 million yuan and projected annual revenue of 500 million yuan upon completion [3]. - General Electric Medical Systems (Tianjin) Co., Ltd. is a major MRI production base for GE globally, with plans to invest 500 million yuan in a research center over the next five years, enhancing its capabilities in superconducting magnets and high-field MRI technology [6]. - Shandong Weigao Orthopedic Materials Co., Ltd. specializes in orthopedic medical devices and has a comprehensive product line, being one of the leading companies in the domestic orthopedic industry [7]. - Henan Randshitan Gene Technology Co., Ltd. focuses on gene diagnosis and treatment technology, with a recent patent application for a kit that detects drug metabolism genes [8]. - Shanghai Huanqing Medical Technology Co., Ltd. is developing an innovative ventricular assist device for acute heart failure treatment, with plans for clinical trials following successful animal testing [9]. - Suzhou Hechun Medical Technology Co., Ltd. specializes in chronic disease management devices, including an innovative insulin pump and a closed-loop artificial pancreas system [10]. - Yuanxin Technology (Shenzhen) Co., Ltd. is the only company developing iron-based absorbable vascular stents, with significant funding rounds and clinical approvals in multiple regions [11]. Group 2: Product Approvals - Seven innovative medical devices have been approved for special review, reflecting the regulatory support for advancements in medical technology [1]. - The devices include a shock wave valve treatment system, MRI systems, and various orthopedic and gene testing products, showcasing a diverse range of applications in the medical field [4][8][10].